Search Results - "Daizadeh, Nadia S"

10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension by Bone, Henry G, Prof, Wagman, Rachel B, MD, Brandi, Maria L, Prof, Brown, Jacques P, MD, Chapurlat, Roland, Prof, Cummings, Steven R, Prof, Czerwiński, Edward, Prof, Fahrleitner-Pammer, Astrid, MD, Kendler, David L, Prof, Lippuner, Kurt, MD, Reginster, Jean-Yves, Prof, Roux, Christian, Prof, Malouf, Jorge, MD, Bradley, Michelle N, PhD, Daizadeh, Nadia S, PhD, Wang, Andrea, MA, Dakin, Paula, MBChB, Pannacciulli, Nicola, MD, Dempster, David W, Prof, Papapoulos, Socrates, Prof

“…Summary Background Long-term safety and efficacy of osteoporosis treatment are important because of the chronic nature of the disease. We aimed to assess the…”
Get full text

Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension study by Adachi, Jonathan D, Bone, Henry G, Daizadeh, Nadia S, Dakin, Paula, Papapoulos, Socrates, Hadji, Peyman, Recknor, Chris, Bolognese, Michael A, Wang, Andrea, Lin, Celia J F, Wagman, Rachel B, Ferrari, Serge

“…Denosumab treatment for up to 8 years in the FREEDOM study and Extension was associated with low fracture incidence. It was not clear whether subjects who…”
Get full text

Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial by Langdahl, Bente L, Libanati, Cesar, Crittenden, Daria B, Bolognese, Michael A, Brown, Jacques P, Daizadeh, Nadia S, Dokoupilova, Eva, Engelke, Klaus, Finkelstein, Joel S, Genant, Harry K, Goemaere, Stefan, Hyldstrup, Lars, Jodar-Gimeno, Esteban, Keaveny, Tony M, Kendler, David, Lakatos, Peter, Maddox, Judy, Malouf, Jorge, Massari, Fabio E, Molina, Jose Fernando, Ulla, Maria Rosa, Grauer, Andreas

“…Previous bisphosphonate treatment attenuates the bone-forming effect of teriparatide. We compared the effects of 12 months of romosozumab (AMG 785), a…”
Get full text

The Effect of Three or Six Years of Denosumab Exposure in Women With Postmenopausal Osteoporosis: Results From the FREEDOM Extension by Bone, Henry G, Chapurlat, Roland, Brandi, Maria-Luisa, Brown, Jacques P, Czerwiński, Edward, Krieg, Marc-Antoine, Mellström, Dan, Radominski, Sebastião C, Reginster, Jean-Yves, Resch, Heinrich, Ivorra, Jose A. Román, Roux, Christian, Vittinghoff, Eric, Daizadeh, Nadia S, Wang, Andrea, Bradley, Michelle N, Franchimont, Nathalie, Geller, Michelle L, Wagman, Rachel B, Cummings, Steven R, Papapoulos, Socrates

“…Context: The Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) extension is evaluating the long-term efficacy and safety of…”
Get full text

RANKL Inhibition With Denosumab Does Not Influence 3‐Year Progression of Aortic Calcification or Incidence of Adverse Cardiovascular Events in Postmenopausal Women With Osteoporosis and High Cardiovascular Risk by Samelson, Elizabeth J, Miller, Paul D, Christiansen, Claus, Daizadeh, Nadia S, Grazette, Luanda, Anthony, Mary S, Egbuna, Ogo, Wang, Andrea, Siddhanti, Suresh R, Cheung, Angela M, Franchimont, Nathalie, Kiel, Douglas P

“…ABSTRACT Atherosclerosis and osteoporosis are chronic diseases that progress with age, and studies suggest aortic calcification, an indicator of…”
Get full text

Safety Observations With 3 Years of Denosumab Exposure: Comparison Between Subjects Who Received Denosumab During the Randomized FREEDOM Trial and Subjects Who Crossed Over to Denosumab During the FREEDOM Extension by Watts, Nelson B, Brown, Jacques P, Papapoulos, Socrates, Lewiecki, E Michael, Kendler, David L, Dakin, Paula, Wagman, Rachel B, Wang, Andrea, Daizadeh, Nadia S, Smith, Shawna, Bone, Henry G

“…ABSTRACT Denosumab is a fully human monoclonal antibody against receptor activator of NF‐κB ligand (RANKL) that decreases osteoclast formation, function and…”
Get full text

The Effect of 3 or 6 Years of Denosumab Exposure in Women With Postmenopausal Osteoporosis: Results From the FREEDOM Extension by Bone, Henry G., Chapurlat, Roland, Brandi, Maria-Luisa, Brown, Jacques P., Czerwinski, Edward, Krieg, Marc-Antoine, Man, Zulema, Mellstrom, Dan, Radominski, Sebastiao C., REGINSTER, Jean-Yves, Resch, Heinrich, Roman Ivorra, Jose A., Roux, Christian, Vittinghoff, Eric, Daizadeh, Nadia S., Wang, Andrea, Bradley, Michelle N., Franchimont, Nathalie, Geller, Michelle L., Wagman, Rachel B., Cummings, Steven R., Papapoulos, Socrates

“…Context:The FREEDOM extension is evaluating the long-term efficacy and safety of denosumab for up to 10 years.Objective:Report results from the first 3 years…”
Get full text

Long-term denosumab treatment of postmenopausal women with osteoporosis: results from the first year extension study of the FREEDOM trial by Chapurlat, R., Papapoulos, Socrates, Bone, Henry G, Brandi, Maria L, Brown, Jacques, Czerwinski, Edward, Daizadeh, Nadia S, Grauer, Andreas, Haller, Christine, Krieg, Marc-Antoine, Libanati, Cesar, Man, Zulema, Mellstrom, Dan, Radominski, Sebastiao, Reginster, Jean-Yves, Resch, Heinrich, Roman Ivora, Jose A, Cummings, Steven R

Get full text